Glucagon-like peptide-1 and cholecystokinin production and signaling in the pancreatic islet as an adaptive response to obesity

Journal of Diabetes Investigation

Volumn 7, Issue , 2016, Pages 44-49

  Linnemann, Amelia K ^a   Davis, Dawn Belt ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Cholecystokinin; Glucagon like peptide 1; Pancreatic islet

Indexed keywords

CHOLECYSTOKININ; GLUCAGON LIKE PEPTIDE 1; PEPTIDOMIMETIC AGENT; INCRETIN;

ADAPTATION; ARTICLE; HORMONAL REGULATION; HORMONE SYNTHESIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; METABOLISM; PARACRINE SIGNALING;

ANIMALS; CHOLECYSTOKININ; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; ISLETS OF LANGERHANS; OBESITY; PARACRINE COMMUNICATION;

EID: 84961279442     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12465     Document Type: Article

References (50)

1. Oleson BJ, McGraw JA, Broniowska KA, et al. Distinct differences in the responses of the human pancreatic β-cell line EndoC-βH1 and human islets to proinflammatory cytokines. Am J Physiol Regul Integr Comp Physiol 2015; 309: R525-R534.
2. Kilimnik G, Kim A, Steiner DF, et al. Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic α-cells in mouse models of β-cell regeneration. Islets 2010; 2: 149-155.
3. Lavine JA, Raess PW, Stapleton DS, et al. Cholecystokinin is up-regulated in obese mouse islets and expands β-cell mass by increasing β-cell survival. Endocrinology 2010; 151: 3577-3588.
4. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011; 17: 1481-1489.
5. Linnemann AK, Neuman JC, Battiola TJ, et al. Glucagon-like peptide-1 Regulates Cholecystokinin Production in beta-cells to Protect from Apoptosis. Mol Endocrinol 2015; 7: 978-987.
6. Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol 2011; 201: 405-411.
7. Lavine JA, Attie AD. Gastrointestinal hormones and the regulation of β-cell mass. Ann N Y Acad Sci 2010; 1212: 41-58.
8. Donath MY, Burcelin R. GLP-1 effects on islets: hormonal, neuronal, or paracrine? Diabetes Care 2013; 2: S145-S148.
9. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
10. Hansen L, Deacon CF, Orskov C, et al. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356-5363.
11. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013; 56: 965-972.
12. Dockray GJ. Cholecystokinin. Curr Opin Endocrinol Diabetes Obes 2012; 19: 8-12.
13. Sandberg E, Ahren B, Tendler D, et al. Cholecystokinin (CCK)-33 stimulates insulin secretion from the perfused rat pancreas: studies on the structure-activity relationship. Pharmacol Toxicol 1988; 63: 42-45.
14. Keller MP, Choi Y, Wang P, et al. A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res 2008; 18: 706-716.
15. Hansen TV. Cholecystokinin gene transcription: promoter elements, transcription factors and signaling pathways. Peptides 2001; 22: 1201-1211.
16. Deavall DG, Raychowdhury R, Dockray GJ, et al. Control of CCK gene transcription by PACAP in STC-1 cells. Am J Physiol Gastrointest Liver Physiol 2000; 279: G605-G612.
17. Nielsen FC, Pedersen K, Hansen TV, et al. Transcriptional regulation of the human cholecystokinin gene: composite action of upstream stimulatory factor, Sp1, and members of the CREB/ATF-AP-1 family of transcription factors. DNA Cell Biol 1996; 15: 53-63.
18. Wang Y, Chandra R, Samsa LA, et al. Amino acids stimulate cholecystokinin release through the Ca2 + -sensing receptor. Am J Physiol Gastrointest Liver Physiol 2011; 300: G528-G537.
19. Chandra R, Wang Y, Shahid RA, et al. Immunoglobulin-like domain containing receptor 1 mediates fat-stimulated cholecystokinin secretion. J Clin Invest 2013; 123: 3343-3352.
20. Irwin N, Frizelle P, Montgomery IA, et al. Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes. Diabetologia 2012; 55: 2747-2758.
21. Irwin N, Montgomery IA, Moffett RC, et al. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice. Biochem Pharmacol 2013; 85: 81-91.
22. Bregenholt S, Møldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem Biophys Res Commun 2005; 330: 577-584.
23. Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass. Diabetes 2006; 55: 1190-1196.
24. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-5158.
25. Eizirik DL, Grieco FA. On the immense variety and complexity of circumstances conditioning pancreatic β-cell apoptosis in type 1 diabetes. Diabetes 2012; 61: 1661-1663.
26. Rondas D, Bugliani M, D'Hertog W, et al. Glucagon-like peptide-1 protects human islets against cytokine-mediated β-cell dysfunction and death: a proteomic study of the pathways involved. J Proteome Res 2013; 12: 4193-4206.
27. Sarkar SA, Gunter J, Bouchard R, et al. Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets. Diabetologia 2007; 50: 1649-1659.
28. Wideman RD, Yu ILY, Webber TD, et al. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc Natl Acad Sci USA 2006; 103: 13468-13473.
29. Lavine JA, Kibbe CR, Baan M, et al. Cholecystokinin expression in the β-cell leads to increased β-cell area in aged mice and protects from streptozotocin-induced diabetes and apoptosis. Am J Physiol Endocrinol Metab 2015; 309: E819-E828.
30. Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiological reviews. Am Physiol Soc 2006; 86: 805-847.
31. Bourassa J, Lainé J, Kruse ML, et al. Ontogeny and species differences in the pancreatic expression and localization of the CCK(A) receptors. Biochem Biophys Res Commun 1999; 260: 820-828.
32. Morisset J, Julien S, Laine J. Localization of cholecystokinin receptor subtypes in the endocine pancreas. J Histochem Cytochem 2003; 51: 1501-1513.
33. Konno K, Takahashi-Iwanaga H, Uchigashima M, et al. Cellular and subcellular localization of cholecystokinin (CCK)-1 receptors in the pancreas, gallbladder, and stomach of mice. Histochem Cell Biol 2014; 143: 301-312.
34. Ning S, Zheng W, Su J, et al. Different downstream signaling of CCKAR regulates distinct functions of CCK in pancreatic β cells. Br J Pharmacol 2015; 172: 5050-5067.
35. Marchetti P, Lupi R, Bugliani M, et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 2012; 55: 3262-3272.
36. Vasu S, Moffett RC, Thorens B, et al. Role of Endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress. PLoS ONE 2014; 9: e101005.
37. Shu L, Matveyenko AV, Kerr-Conte J, et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 2009; 18: 2388-2399.
38. Flamez D, Gilon P, Moens K, et al. Altered cAMP and Ca2 + signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 1999; 48: 1979-1986.
39. Li Y. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2002; 278: 471-478.
40. Quoyer J, Longuet C, Broca C, et al. GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a β-arrestin 1-mediated ERK1/2 activation in pancreatic β-cells. J Biol Chem 2010; 285: 1989-2002.
41. Shin S, Le Lay J, Everett LJ, et al. CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse. Mol Metab 2014; 3: 803-812.
42. Ali S, Lamont BJ, Charron MJ, et al. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest 2011; 121: 1917-1929.
43. Kim A, Miller K, Jo J, et al. Islet architecture: a comparative study. Islets 2009; 1: 129-136.
44. Suarez-Pinzon WL, Power RF, Yan Y, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 2008; 57: 3281-3288.
45. Dalboge LS, Almholt DLC, Neerup TSR, et al. The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice. J Pharmacol Exp Ther 2014; 350: 353-360.
46. Pieber TR, Deller S, Korsatko S, et al. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab 2015; 17: 742-750.
47. Schopman JE, Hoekstra JBL, Frier BM, et al. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. Diabetes Obes Metab 2015; 17: 546-553.
48. Irwin N, Hunter K, Montgomery IA, et al. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice. Diabetes Obes Metab 2013; 15: 650-659.
49. Irwin N, Pathak V, Flatt PR. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice. Diabetes 2015; 64: 2996-3009.
50. Trevaskis JL, Sun C, Athanacio J, et al. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents. Diabetes Obes Metab 2015; 17: 61-73.